Latest news for Pressance (OTC:PSSKF) Stock

Pressance Corp is a real estate business based in Japan. The company earns all revenue domestically. Pressance engages in several activities related to the development and sale of real estate, including the sale of newly built apartments, trading and brokering land and condominiums, building management, parking lot operation, management of apartment buildings, leasing, and general real estate management activities. In addition, the company provides consultancy services such as real estate planning and research.

Pressance Corp

<p>JP Morgan  analyst Matthew Boss   maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Neutral and raises the price target from $20 to $23.</p>


News

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on VF, Raises Price Target to $23

<p>JP Morgan  analyst Andrea Teixeira   maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Neutral and raises the price target from $74 to $79.</p>


JP Morgan Maintains Neutral on Estee Lauder Cos, Raises Price Target to $79

WIIM

PLBY

PLBY Group shares are trading higher after the company said it would retain its Honey Birdette business.

DXCM

DexCom shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $86 to $104.

<p>Truist Securities  analyst Jamie Cook   maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Hold and raises the price target from $42 to $43.</p>


CGNX

Truist Securities Maintains Hold on Cognex, Raises Price Target to $43

<p><i>Lucid Gravity Touring will start at $113,5001&nbsp;CDN with Grand Touring starting at $134,5001 CDN</i></p>
<p>NEWARK, Calif., Jan. 16, 2025 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>), maker of the world's most advanced electric vehicles, today announced Canadian pricing for the groundbreaking Lucid Gravity SUV. The Lucid Gravity Touring will be priced from $113,5001 CDN, while the Lucid Gravity Grand Touring will start at $134,5001 CDN. Orders for the Lucid Gravity Grand Touring model, offering 828 horsepower and a projected range surpassing 720 kilometres2, will open for Canadian customers soon, with the Lucid Gravity Touring added to the model lineup in late 2025.</p>


LCID

Lucid Group Announces Canadian Pricing For Lucid Gravity SUV: Touring Starts At $113,500 CDN, Grand Touring At $134,500 CDN; Orders For Grand Touring Model Open Soon

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>Name</strong></th>
<th align="right"><strong>Price</strong></th>
<th align="right"><strong>Change ($)</strong></th>
<th align="right"><strong>Change (%)</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">76.7300</td>
<td align="right">0.50</td>
<td align="right">0.65</td>
<td>12.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">233.4400</td>
<td align="right">1.15</td>
<td align="right">0.49</td>
<td>14.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">40.3400</td>
<td align="right">0.15</td>
<td align="right">0.37</td>
<td>1.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">87.3600</td>
<td align="right">0.32</td>
<td align="right">0.36</td>
<td>855</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.9399</td>
<td align="right">0.15</td>
<td align="right">0.19</td>
<td>981</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">227.5300</td>
<td align="right">0.25</td>
<td align="right">0.10</td>
<td>1.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">135.3500</td>
<td align="right">0.06</td>
<td align="right">0.04</td>
<td>25.1K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>Name</strong></th>
<th align="right"><strong>Price</strong></th>
<th align="right"><strong>Change ($)</strong></th>
<th align="right"><strong>Change (%)</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">139.98</td>
<td align="right">-0.59</td>
<td align="right">-0.42</td>
<td>7.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">96.75</td>
<td align="right">-0.35</td>
<td align="right">-0.37</td>
<td>430</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">92.28</td>
<td align="right">-0.29</td>
<td align="right">-0.32</td>
<td>22.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">49.46</td>
<td align="right">-0.02</td>
<td align="right">-0.05</td>
<td>425.7K</td>
</tr>
</tbody>
</table>
<p><a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. </p>
<p><em>For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.</em> </p>


Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For January 16, 2025

<p>JP Morgan  analyst Andrea Teixeira   maintains SharkNinja (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) with a Overweight and raises the price target from $120 to $127.</p>


JP Morgan Maintains Overweight on SharkNinja, Raises Price Target to $127

<p>Katapult Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>), an e-commerce-focused financial technology company, today announced gross originations for the fourth quarter ended December 31, 2024.</p>
<p>Katapult's gross originations were approximately $75.2 million for the fourth quarter, an increase of 11.3% year-over-year and above the 6-8% growth range the company provided on November 6, 2024. This is expected to be the ninth consecutive quarter of year-over-year gross originations growth and the second highest level of gross originations volume in the company's history.</p>
<p>Key drivers of the strong performance during the quarter include:</p>
<ul>
<li>Growth in application volume. Total lease application volume grew approximately 50% year-over-year; this includes approximately 51% growth in new customer lease application volume and 50% growth in existing customer lease application volume.</li>
<li>Strong engagement from repeat customers. Approximately 61.5% of gross originations in the fourth quarter of 2024 came from repeat customers1.</li>
<li>Continued engagement with Katapult Pay&#xAE; ("KPay") and our app. KPay gross originations grew approximately 52% year-over-year.</li>
</ul>


Guidance

KPLT

Katapult Announces $75.2M Q4 Gross Originations, Up 11.3% YoY, Surpassing 6%-8% Growth Expectation; KPay Originations Up 52% YoY

ROLR

High Roller Technologies Enters A Strategic Partnership With Iconvert To Focus On Player Acquisition, Player Retention, And Helping to Convert More Users Into Depositors Across All Of The Company's Markets

Vail Resorts Season-To-Date Total Skier Visits Down 0.3%

<p>JP Morgan  analyst Andrea Teixeira   maintains Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) with a Neutral and raises the price target from $9 to $10.</p>


JP Morgan Maintains Neutral on Newell Brands, Raises Price Target to $10

U.S. Bancorp shares are trading lower after the company reported worse-than-expected Q4 revenue results.

PLBY Group To Retail Its Honey Birdette Business Following The Closing Of Byborg Enterprises License Agreement; Says Now Expects To Generate FY Revenue Of ~$120M And Be Cash Flow Positive In 2025

<p>JP Morgan  analyst Matthew Boss   maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Overweight and raises the price target from $428 to $437.</p>


LULU

JP Morgan Maintains Overweight on Lululemon Athletica, Raises Price Target to $437

<p><i>Initial plans target European clinical trials while providing standard testing to clinicians for individual patients</i></p>
<p><i>There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe</i></p>
<p>PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx&#xAE; drug response assay in Europe and expanded availability in the United States. The ChemoFx&#xAE; treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest over time.</p>
<p>The ChemoFx&#xAE; drug response assay is a treatment selection marker for chemotherapies that quantifies an individual cancer patients' <i>in vitro</i> tumor response to various chemotherapeutic agents.</p>


Biotech

General

POAI

Predictive Oncology Announces European Launch Of ChemoFx Drug Response Assay Targeting 250K Annual Gynecologic Cancer Diagnoses; U.S. Expansion Also Planned

Contracts

Standard Lithium And Equinor Finalize $225M Grant From The U.S. Department Of Energy For The South West Arkansas Project

<p>JP Morgan  analyst Kian Abouhossein   maintains Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) with a Overweight and raises the price target from $550 to $605.</p>


JP Morgan Maintains Overweight on Goldman Sachs Gr, Raises Price Target to $605

PALI

Palisade Bio Completes All Five Single Ascending Dose Cohorts And Commences Multiple Ascending Dose Cohorts In Phase 1a/b Trial Of PALI-2108 For Ulcerative Colitis; Co. On Track To Report Topline Data In 1H 2025

JNVR

Janover Regains Compliance With Nasdaq Minimum Requirements

Pressance ( ($JP:3254) ) has shared an update. Pressance Corporation has announced its board's decision to support a tender offer by its controllin...

Comments

Pressance

News

Latest news for Pressance (OTC:PSSKF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga